Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Receives $3.3M Grant to Develop Ebola MDx Assay

NEW YORK (GenomeWeb) – Cepheid said today that it has been awarded a grant for up to $3.3 million to develop a molecular diagnostic test for Ebola.

The Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation awarded the grant to the Sunnyvale, Calif.-based firm to develop Xpert Ebola, which will run on Cepheid's installed base of more than 3,500 GeneXpert Systems in developing countries, including more than 1,000 systems in Africa. The test is anticipated to be available on an emergency-use-only basis. For now, Cepheid said that it expects the test will use oral swabs or capillary whole-blood specimen.

"We are leveraging our significant investments in [the] development of ultrasensitive HIV and [tuberculosis] detection technologies and are borrowing on previous experience with an Ebola project to expedite delivery of the initial prototype and emergency-use-only product," Cepheid Chief Medical and Technology Officer David Persing said in a statement. "We expect this technology to facilitate high-throughput testing requirements in Ebola treatment units, as well as deployment of mobile laboratories for field surveillance."

Additionally, Cepheid said that it and the Gates Foundation are evaluating the deployment of the firm's RemoteXpert cloud-based monitoring software. The product is currently being used in a pilot phase for TB testing in South Africa and India and has collected real-time data streams from about 2.5 million cases being assessed for TB and drug resistance.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.